{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-093948","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.882624+00:00","generated_at":"2026-05-15T21:16:07.443721+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lineage Q4 net income $0.9M, full-year loss $63.5M; cash runway into Q2 2028","bullets":["Q4 2025 revenue $6.6M (up from $2.9M YoY); net income $0.9M ($0.004 EPS) vs net loss $3.3M ($0.02 loss) in Q4 2024.","Full-year 2025 net loss $63.5M ($0.28/share) vs $18.6M ($0.09/share) in 2024; driven by non-cash warrant remeasurement ($37.9M) and VAC impairment ($14.8M).","Cash $55.8M at Dec 31, 2025; plus $5.4M from warrant exercises in March 2026; expected to support operations into Q2 2028.","Achieved first milestone under Roche/Genentech collaboration for OpRegen; 36-month Phase 1/2a data shows sustained visual acuity gains.","Launched Type 1 diabetes research initiative; treated first chronic SCI patient in OPC1 DOSED study with no safety events at 180 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-093948","json":"https://secwatch.observer/filing/0001193125-26-093948.json","markdown":"https://secwatch.observer/filing/0001193125-26-093948.md","text":"https://secwatch.observer/filing/0001193125-26-093948.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000119312526093948/0001193125-26-093948-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000119312526093948/lctx-20260305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:16:07.443721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"436513e918161cf83b13311f987a789ca7195d85","claim":"Lineage Cell Therapeutics, Inc. reported financial results for quarter and year ended December 31, 2025.","evidence_excerpt":"On March 5, 2026, Lineage Cell Therapeutics, Inc. issued a press release announcing financial results for the quarter and year ended December 31, 2025","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526093948/0001193125-26-093948-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter and year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}